ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat

Neuroscience Letters

Volumn 452, Issue 3, 2009, Pages 252-257

  Reid, Martin J ^a   Cross, Alison K ^a   Haddock, Gail ^a   Allan, Stuart M ^c   Stock, Chris J ^c   Woodroofe, M Nicola ^a   Buttle, David J ^b   Bunning, Rowena A D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

ADAMTS 9; Cerebral ischaemia; Stroke; tMCAo

Indexed keywords

ADAMTS 9 ENZYME; METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; IN SITU HYBRIDIZATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; BRAIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; NEURONS; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 60849099310     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.01.058     Document Type: Article

References (33)

1. Brakebusch C., Seidenbecher C.I., Asztely F., Rauch U., Matthies H., Meyer H., Krug M., Böckers T.M., Zhou X., Kreutz M.R., Montag D., Gundelfinger E.D., and Fässler R. Brevican-deficient mice display impaired hippocampal CA1 long-term potentiation but show no obvious deficits in learning and memory. Mol. Cell. Biol. 22 (2002) 7417-7427
2. Chen H., Hernden M.E., and Lawler J. The cell biology of thrombospondin-1. Matrix Biol. (2000) 597-614
3. Copin J.-C., Goodyear M.-C., Gidday J.M., Shah A.R., Gascon E., Dayer A., Morel D.M., and Gasche Y. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur. J. Neurosci. 22 (2005) 1597-1608
4. Cross A.K., Haddock G., Stock C.J., Allan S., Surr J., Bunning R.A.D., Buttle D.J., and Woodroofe M.N. ADAMTS-1 and -4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes. Brain Res. 1088 (2006) 19-30
5. Cross N.A., Chandrasekharan S., Jokonya N., Fowles A., Hamdy F.C., Buttle D.J., and Eaton C.L. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15 and TIMP-3 by TGFβ1 in prostate cells: relevance to the accumulation of versican. Prostate 63 (2005) 269-275
6. Demircan K., Hirohata S., Nishida K., Hatipoglu O.F., Oohashi T., Yonezawa T., Apte S.S., and Ninomiya Y. ADAMTS-9 is synergistically induced by interleukin-1β and tumour necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum. 52 (2005) 1451-1460
7. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26 (2006) 1465-1478
8. Galtrey C.M., and Fawcett J.W. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res. Rev. 54 (2007) 1-18
9. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., and Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 279 (2004) 10042-10051
10. Gibson R.M., Rothwell N.J., and Le Feuvre R.A. CNS injury: the role of the cytokine IL-1. Vet. J. 168 (2004) 230-237
11. Haddock G., Cross A.K., Plumb J., Surr J., Buttle D.J., Bunning R.A.D., and Woodroofe M.N. Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult. Scler. 12 (2006) 386-396
12. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by the tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 494 (2001) 192-195
13. Huang J., Upadhyay U.M., and Tamargo R.J. Inflammation in stroke and cerebral ischemia. Surg. Neurol. 66 (2006) 232-245
14. Jones G.C., and Riley G.P. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res. Ther. 7 (2005) 160-169
15. Jungers K.A., Le Goff C., Somerville R.P.T., and Apte S.S. Adamts 9 is widely expressed during mouse embryo development. Gene Expr. Patterns 5 (2005) 609-617
16. Kelly M.A., Shuaib A., and Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol. 200 (2006) 38-49
17. Koo B.-H., Longré J.-M., Somerville R.P.T., Alexander J.P., Leduc R., and Apte S.S. Cell-surface processing of pro-ADAMTS9 by furin. J. Biol. Chem. 281 (2006) 12485-12494
18. Koo B.-H., Longpré J.-M., Somerville R.P.T., Alexander J.P., Leduc R., and Apte S.S. Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide. J. Biol. Chem. 282 (2007) 16146-16154
19. Lee S.-R., Kim H.-Y., Rogowska J., Zhao B.-Q., Bhide P., Parent J.M., and Lo E.H. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci. 26 (2006) 3491-3495
20. -ΔΔCT method. Methods 25 (2001) 402-408
21. Perera M.N., Ma H.K., Arakawa S., Howells D.W., Markus R., Rowe C.C., and Donnan G.A. Inflammation following stroke. J. Clin. Neurosci. 13 (2006) 1-8
22. Plumb J., Cross A.K., Surr J., Haddock G., Smith T., Bunning R.A.D., and Woodroofe M.N. ADAM-17 TIMP3 protein and mRNA expression in spinal cord white matter of rats with acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164 (2005) 1-9
23. Porter S., Clark I.M., Kevorkian L., and Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 386 (2005) 15-27
24. Rauch U., Zhou X.-H., and Roos G. Extracellular matrix alterations in brains lacking four of its components. Biochem. Biophys. Res. Commun. 328 (2005) 608-617
25. Rodríguez-Manzaneque J.C., Milchanowski A.B., Dufour E.K., Leduc R., and Iruela-Arispe M.L. Characterization of METH-1/ADAMTS-1 processing reveals two distinct active forms. J. Biol. Chem. 275 (2000) 33471-33479
26. Rodríguez-Manzaneque J.C., Westling J., Thai S.N.-M., Luque A., Knauper V., Murphy G., Sandy J.D., and Iruela-Arispe M.L. ADAMTS1 cleaves aggrecan at multiple sites and is diferentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. 293 (2002) 501-508
27. Somerville R.P.T., Longpre J.-M., Jungers K.A., Engle J.M., Ross M., Evanko S., Wight T.N., Leduc R., and Apte S.S. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabitis elegans GON-1. J. Biol. Chem. 278 (2003) 9503-9513
28. Tian Y.F., Zhang P.B., Xiao X.L., Zhang J.S., Zhao T.T., Kang Q.Y., Chen X.L., Qiu F., and Liu Y. The quantification of ADAMTS expression in an animal model of cerebral ischemia using real-time PCR. Acta. Anaesth. Scand. 51 (2007) 158-164
29. Yakota N., Uchijima M., Nishizawa S., Namba H., and Koide Y. Identification of differentially expressed genes in rat hippocampus after transient global cerebral ischemia using Subtractive cDNA cloning based on polymerase chain reaction. Stroke 32 (2001) 168-174
30. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell. Mol. Life Sci. 57 (2000) 276-289
31. K.O. Yaykasli, T. Oohashi, S. Hirohata, O.F. Hatipoglu, K. Inagawa, K. Demircan, Y. Ninomiya, ADAMTS9 activation by interleukin 1b via NFATc1 in OUMS-27 chondrosarcoma cells and in human chondrocytes, Mol. Cell. Biochem, in press.
32. Yiu G., and He Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7 (2006) 617-626
33. Zeng W., Corcoran C., Collins-Racie L.A., LaVallie E.R., Morris E.A., and Flannery C.R. Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18. Biochim. Biophys. Acta 1760 (2006) 517-524